• BioMarin's CEO On Its Product Pipeline   Tuesday, 8 Jan 2013 | 2:20 PM ET
    BioMarin's CEO On Its Product Pipeline

    The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.

  • Biotech Stocks Rally   Tuesday, 8 Jan 2013 | 1:32 PM ET
    Biotech Stocks Rally

    CNBC's Seema Mody reports the pharmaceutical and biotech sectors rally as the JPMorgan conference kicks off its second day.

  • Building the Next Big Biotech   Monday, 7 Jan 2013 | 10:20 AM ET
    Building the Next Big Biotech

    Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.

  • US Clears DNA Firm’s Acquisition by Chinese Monday, 31 Dec 2012 | 11:56 AM ET

    The U.S. has given national security clearance to the purchase of an American DNA sequencing company by a Chinese firm, The New York Times reports.

  • McAfee: I Am Innocent   Tuesday, 13 Nov 2012 | 2:50 PM ET
    McAfee: I Am Innocent

    Anti-virus software pioneer John McAfee is now firing back, reports CNBC's Robert Frank.

  • DuPont to Cut 1,500 Jobs as Earnings Miss Estimates Tuesday, 23 Oct 2012 | 11:02 AM ET
    Korean Firm Indicted in Alleged Theft of DuPont Secrets

    DuPont reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday, and announced plans to cut 1,500 jobs.

  • Why Investors Like Pharma Stocks   Monday, 8 Oct 2012 | 2:23 PM ET
    Why Investors Like Pharma Stocks

    Pharmaceuticals continue to be an attractive sector for earnings and dividend growth, and CNBC's Seema Mody reports on how companies like Pfizer are faring.

  • Biotech, Pharma Show Healthy Gains   Monday, 8 Oct 2012 | 7:55 AM ET
    Biotech, Pharma Show Healthy Gains

    If you're looking for beta, biotech might be your answer, reports CNBC's Seema Mody.

  • Healthcare cost

    Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.

  • Savient Bulls Come Back for More Wednesday, 19 Sep 2012 | 7:30 AM ET

    Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.

  • Biotech—Outperforming for the Right Reasons Monday, 17 Sep 2012 | 4:38 PM ET

    The NYSE Arca Biotech index spacer hit an all-time high Monday, as investors continue to seek out the group for its above average growth prospects.

  • AstraZeneca Poaches Genentech Boss From Roche Tuesday, 28 Aug 2012 | 2:04 AM ET
    AstraZeneca Poaches Genentech Boss From Roche

    AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.

  • Bristol’s Hep C Drug Blowup May Benefit These Stocks Thursday, 2 Aug 2012 | 10:51 AM ET

    Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.

  • Jim Cramer

    Investors need to see this as a speculative stock and take some profits as they come in, he said.

  • Cramer’s 5 Recession-Resistant Stocks Tuesday, 10 Jul 2012 | 12:55 PM ET
    Abbott Labs

    In the wake of Friday’s disappointing jobs report, “Mad Money” host Jim Cramer thinks investors need to prepare for the possibility of a recession.

  • Anti-Obesity Drug a Big Win for Biotech Friday, 29 Jun 2012 | 1:36 PM ET

    With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.

  • Is Celgene a Broken Stock or a Broken Company? Thursday, 28 Jun 2012 | 6:20 PM ET

    “Mad Money” host Jim Cramer has the answer.

  • Broken Stock or Broken Company?   Thursday, 28 Jun 2012 | 6:15 PM ET
    Broken Stock or Broken Company?

    Last week, Celgene announced it was pulling its Revlimid application in Europe, and Mad Money host Jim Cramer explains why he thinks investors should buy into the stock now.

  • Biotech Stocks Immune to Mandate?   Thursday, 28 Jun 2012 | 11:30 AM ET
    Biotech Stocks Immune to Mandate?

    A look at the impact of the Supreme Court's ruling on biotech stocks, with James Greenwood, BIO CEO.

  • Biotech & Drug Stocks: Scotus Ruling Impact   Wednesday, 27 Jun 2012 | 5:15 PM ET
    Biotech & Drug Stocks: Scotus Ruling Impact

    The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.